Mount Sinai Health System and PerkinElmer Collaborate to Accelerate COVID-19 Screening

September 22, 2021

Program offers practical, routine and reliable SARS-CoV-2 tests to protect New York’s students and communities

WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced its collaboration with the Mount Sinai Health System to increase accessibility of SARS-CoV-2 testing in New York City. The laboratory system located at the Mount Sinai Beth Israel campus now has the capacity to process 25,000 (and ultimately up to 100,000) tests per day with PerkinElmer’s instrument and reagents.

RT-PCR testing is the most accurate method for detecting SARS-CoV-2, the virus that causes COVID-19. The relationship forged between Mount Sinai Health System and PerkinElmer makes gold standard RT-PCR based SARS-CoV-2 screening available to schools and businesses throughout New York City.

HOW: According to the U.S. Food & Drug Administration (FDA) companion resource, a highly sensitive RT-PCR test should be used for screening asymptomatic individuals. The PerkinElmer New Coronavirus Nucleic Acid Detection Kit is the most sensitive commercially available COVID-19 molecular diagnostic test authorized for emergency use, as reported by FDA’s reference panel study, and is ideally suited to support screening programs.

WHY: “Mount Sinai has shown extraordinary commitment and leadership in scientific and clinical efforts to beat this pandemic. We developed one of the first highly sensitive antibody tests, pioneered innovative therapies to treat COVID-19, and are researching the lingering effects suffered by ‘long-haulers.’ The Mount Sinai Covid Lab and testing program is designed to help our community in slowing transmission and getting us back to normal,” said David L. Reich, MD, President and Chief Operating Officer, The Mount Sinai Hospital. “We are proud to partner with PerkinElmer in expanding our testing capacity and footprint to serve our communities.”

“PerkinElmer is proud to lend its expertise in SARS-CoV-2 testing by supplying and supporting the Mount Sinai Health System with reagents, automation equipment and consumables that are critical to meet laboratory operational needs,” said Arvind Kothandaraman, managing director, specialty diagnostics at PerkinElmer. “We are humbled and inspired by the work of our long-standing collaborators at Mount Sinai, who go above and beyond to help underserved communities in New York City that have been profoundly affected by the pandemic.”

MORE: As the Delta variant is threatening to upend another school year, RT-PCR testing remains the preferred method for COVID-19 diagnostics. PerkinElmer’s comprehensive SARS-CoV-2 portfolio includes high throughput RNA extraction, RT-PCR, antigen testing, workflow automation, ELISA, chemiluminescence, time-resolved fluorescence and lateral flow based serology testing.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. We advance medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 free-standing joint-venture centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked in U.S. News & World Report’s “Honor Roll” of the top 20 U.S. hospitals and among the top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Urology, and Rehabilitation. Mount Sinai Kravis Children’s Hospital is ranked in U.S. News & World Report’s “Best Children’s Hospitals” among the country’s best in four out of 10 pediatric specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked among the Top 20 nationally for ophthalmology. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools,” aligned with a U.S. News & World Report “Honor Roll” Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and top five globally, and Mount Sinai Morningside as top 20 globally, and “The World’s Best Specialized Hospitals” ranks Mount Sinai Heart as No. 1 in New York and No. 5 globally and the Division of Gastroenterology as No. 5 globally. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com.

###

Media Relations:
Chet Murray
(781) 663-5728
chet.murray@perkinelmer.com